5 Penny Stocks Insiders Are Buying: Tellurian, Accelerate Diagnostics And More




When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

Tellurian

  • The Trade: Tellurian Inc. (NASDAQ:TELL) Director Claire Harvey acquired a total of 16000 shares at an average price of $3.19. To acquire these shares, it cost $51,072.00.
  • What’s Happening: Tellurian, in November, reported a Q3 loss of $0.04 per share.
  • What Tellurian Does: Tellurian Inc is a US-based independent oil and gas exploration and production company. It is developing a portfolio of natural gas production, LNG marketing, and infrastructure assets that includes an LNG terminal facility and related pipelines.

Accelerate Diagnostics

  • The Trade: Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Director Jack Schuler acquired a total of 131219 shares at an average price of $4.00. The insider spent $524,441.91 to buy those shares.
  • What’s Happening: Accelerate Diagnostics recently said preliminary Q4 sales and FY21 sales are expected to be below estimates.
  • What Accelerate Diagnostics Does: Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm’s core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic.

SurgePays

  • The Trade: SurgePays, Inc. (NASDAQ:SURG) Director David A May acquired a total of 92172 shares at an average price of $1.95. To acquire these shares, it cost $179,655.74.
  • What’s Happening: SurgePays reported 30,000 SurgePhone wireless subscribers in December.
  • What SurgePays Does: Surgepays Inc is a fintech company. It provides services to financial technology, telecommunications, and digital media companies.

Hillstream BioPharma

  • The Trade: Hillstream BioPharma, Inc. (NASDAQ:HILS) Director Leonard Mazur acquired a total of 123733 shares at an average price of $3.36. The insider spent $415,945.60 to buy those shares.
  • What’s Happening: Hillstream BioPharma recently reported closing of Initial Public Offering.
  • What Hillstream BioPharma Does: Hillstream BioPharma Inc is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers.

Entera Bio

  • The Trade: Entera Bio Ltd. (NASDAQ:ENTX) Director Yonatan Malca acquired a total of 7232 shares at an average price of $2.74. The insider spent $19,815.68 to buy those shares.
  • What’s Happening: Entera Bio recently announced successful EB613 end-of-Phase 2 meeting with the FDA.
  • What Entera Bio Does: Entera Bio Ltd is a clinical-stage biopharmaceutical company which focuses on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical need.



Source link



Copyright © 2022 Billionaire Club Co LLC. All rights reserved

Chat
Loading the chat ...